A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
Launched by LYPHOMED · Aug 30, 2001
Trial Information
Current as of January 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following are excluded:
- • Previous history of adverse reaction to pentamidine.
- • History of asthma.
- • Pulmonary Kaposi's sarcoma.
- Patients with the following are excluded:
- • Previous history of adverse reaction to pentamidine.
- • History of asthma.
- • Pulmonary Kaposi's sarcoma.
- • Inability to understand the consent procedure.
- • All patients hospitalized at Cedars-Sinai Medical Center with AIDS and possible Pneumocystis carinii pneumonia (PCP) will be eligible.
- • Patients with HIV antibody or AIDS and a clinical presentation suggesting PCP are eligible.
About Lyphomed
Lypohomed is a leading clinical trial sponsor dedicated to advancing innovative therapies and improving patient outcomes in the pharmaceutical and biotechnology sectors. With a focus on high-quality research and development, Lypohomed collaborates with a network of healthcare professionals and institutions to design and execute rigorous clinical trials. The organization emphasizes ethical practices, regulatory compliance, and patient safety, ensuring that all studies are conducted with the utmost integrity. Through its commitment to scientific excellence and collaboration, Lypohomed aims to bring transformative treatments to market and address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rosemont, Illinois, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials